Colorectal Cancer Clinical Trial
Official title:
Effects of Sleep Quality and Mental Status on Early Postoperative Recurrence and Prognosis in Patients With Colorectal Cancer: a Prospective Observational Cohort Study
Verified date | May 2024 |
Source | Fudan University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This is a prospective observational cohort study to explore the effects of sleep quality and mental status on early postoperative recurrence and prognosis in patients with colorectal cancer.
Status | Enrolling by invitation |
Enrollment | 500 |
Est. completion date | December 31, 2027 |
Est. primary completion date | December 31, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Preoperative fibrocolonoscopy and pathological examination confirmed colorectal cancer; 2. Age 18 ~ 80 years old; 3. Baseline clinical stage TNM ? to ? : cT1-4N0-2M0 (AJCC-8 version); 4. The United States Eastern Oncology Consortium (ECOG) physical status score was 0 to 2 points; 5. Laboratory examination results before admission met the following surgical conditions: neutrophil (ANC) =1.5×109/L, platelets (PLT) = 100×109/L, total bilirubin (TBI) =1.5× upper limit of normal (2mg/dl), alanine aminotransferase (ALT), aspartate aminotransferase (AST) =2× upper limit of normal; Coagulation parameters in the normal range; 6. Able to complete the required research questionnaire independently or with the assistance of the researcher; 7. Patients were willing to undergo regular follow-up after surgery and had no psychological, family, social, or geographic constraints that affected protocol compliance and follow-up time; 8. Patients and their families can understand and are willing to participate in this clinical study, and sign informed consent. Exclusion Criteria: 1. Under 18 years of age or over 80 years of age; 2. Have a family history of severe mental illness; 3. People with mental illness or intellectual disability who cannot correctly describe their feelings; 4. The patient has severe systemic infection; 5. No radical operation was performed during the operation due to various reasons; 6. Patients with intestinal obstruction, intestinal perforation, intestinal bleeding, peritonitis, etc. requiring emergency surgery; 7. Merge other parts of the transfer; 8. Have serious heart, lung, liver and kidney diseases, can not tolerate surgery; 9. Active stage of liver disease or abnormal liver function, ALT, AST, TBIL is more than 2 times the upper limit of normal value; 10. Renal function damage, Cr = 2 times the upper limit of normal value or BUN = 2 times the upper limit of normal value; 11. The subject's blood white blood cells are lower than the lower limit of normal, or platelets are lower than the lower limit of normal, or there are other blood system diseases; 12. Severe coagulation mechanism disorder and bleeding tendency; 13. Serious uncontrolled medical disease, recent history of myocardial infarction (within 3 months); Acute infection; 14. Patients with uncontrolled severe hypertension and severe diabetes after intervention; 15. The researchers considered that other candidates were not suitable for inclusion in this study. |
Country | Name | City | State |
---|---|---|---|
China | Fudan University Shanghai Cancer Center | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Ma Yanlei |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Disease-free survival (DFS) | The duration between the date after surgery to the date of any recurrence or death firstly | through study completion, an average of 1 year | |
Primary | Overall Survival | Time from the start of surgical randomization to death (from any cause) | through study completion, an average of 1 year | |
Primary | Effect of sleep quality and mental state on early recurrence and prognosis of patients with colorectal cancer after surgery | The correlation of GAD-7 scale score, PHQ-9 scale score and ESAS scale score with Disease-free survival (DFS), Overall Survival and tumor-free survival rate of patients was analyzed | through study completion, an average of 1 year | |
Secondary | Tumor markers CEA, CA19-9 was used to determine recurrence in patients with colorectal cancer enrolled in the study. | Tumor markers CEA, CA19-9 was used to determine recurrence in patients with colorectal cancer enrolled in the study. 1, 3, 6, 12, 18, 24 months after the operation until the observation endpoint appeared. | From date of randomization until the date of death from any cause, whichever came first, assessed up to 100 months | |
Secondary | Enteroscope was used to determine recurrence in patients with colorectal cancer enrolled in the study. | Enteroscope was used to determine recurrence in patients with colorectal cancer enrolled in the study. 1, 3, 6, 12, 18, 24 months after the operation until the observation endpoint appeared. | From date of randomization until the date of death from any cause, whichever came first, assessed up to 100 months | |
Secondary | Physical examination was used to determine recurrence in patients with colorectal cancer | Physical examination was used to determine recurrence in patients with colorectal cancer.1, 3, 6, 12, 18, 24 months after the operation until the observation endpoint appeared. | From date of randomization until the date of death from any cause, whichever came first, assessed up to 100 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |